Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …

Purpose: Although KRAS represents the most commonly mutated oncogene, it has long
been considered an “undruggable” target. Novel covalent inhibitors selective for the …

Despite its importance in human cancers, including colorectal cancers (CRC), oncogenic
KRAS has been extremely challenging to target therapeutically. To identify potential …

Profiling candidate therapeutics with limited cancer models during preclinical development
hinders predictions of clinical efficacy and identifying factors that underlie heterogeneous …

Immune evasion is a hallmark of KRAS-driven cancers, but the underlying causes remain
unresolved. Here, we use a mouse model of pancreatic ductal adenocarcinoma to inactivate …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

Purpose: KRAS is among the most commonly mutated oncogene in cancer including non–
small cell lung cancer (NSCLC). In early clinical trials, inhibitors targeting G12C-mutant …

Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic
agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) …

ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …